{"id":563241,"date":"2026-09-18T23:29:55","date_gmt":"2026-09-18T21:29:55","guid":{"rendered":"https:\/\/medizinonline.com\/des-possibilites-elargies-grace-a-des-classes-de-principes-actifs-innovantes\/"},"modified":"2026-09-18T23:30:00","modified_gmt":"2026-09-18T21:30:00","slug":"des-possibilites-elargies-grace-a-des-classes-de-principes-actifs-innovantes","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/des-possibilites-elargies-grace-a-des-classes-de-principes-actifs-innovantes\/","title":{"rendered":"Des possibilit\u00e9s \u00e9largies gr\u00e2ce \u00e0 des classes de principes actifs innovants"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Les syndromes myasth\u00e9niques r\u00e9sultent d\u2019un trouble de la transmission neuromusculaire. Bien qu\u2019il n\u2019existe toujours pas de traitement curatif pour la myasth\u00e9nie grave, les options th\u00e9rapeutiques m\u00e9dicamenteuses disponibles aujourd\u2019hui permettent des approches th\u00e9rapeutiques diff\u00e9renci\u00e9es visant \u00e0 am\u00e9liorer durablement la qualit\u00e9 de vie des personnes concern\u00e9es. Dans ce contexte, outre l\u2019activit\u00e9 de la maladie, le profil des anticorps rev\u00eat une importance th\u00e9rapeutique croissante, notamment pour l\u2019indication des inhibiteurs du compl\u00e9ment C5 ou des bloqueurs de FcRn.  <\/strong><\/p>\n\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fdes-possibilites-elargies-grace-a-des-classes-de-principes-actifs-innovantes%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Les syndromes myasth\u00e9niques r\u00e9sultent d\u2019un trouble de la transmission neuromusculaire. Bien qu\u2019il n\u2019existe toujours pas de traitement curatif pour la myasth\u00e9nie grave, les options th\u00e9rapeutiques m\u00e9dicamenteuses disponibles aujourd\u2019hui permettent des&#8230;&hellip;... <\/p>\n<div class=\"pmpro\"><div class=\"pmpro_card pmpro_content_message\"><div class=\"pmpro_card_content\">Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich <br \/><a href=\"https:\/\/medizinonline.com\/fr\/mon-compte\/paquets\/\">Jetzt beitreten<\/a><\/div><div class=\"pmpro_card_actions pmpro_font-medium\">Already a member? <a href=\"https:\/\/medizinonline.com\/fr\/se-connecter\/?redirect_to=https%3A%2F%2Fmedizinonline.com%2Ffr%2Fdes-possibilites-elargies-grace-a-des-classes-de-principes-actifs-innovantes%2F\">Connectez-vous ici<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":562675,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Myasth\u00e9nie grave : traitements immunomodulateurs pour la prise en charge \u00e0 long terme  ","footnotes":"","_members_access_role":[],"_members_access_error":""},"category":[11549,11527,11315,11383,11444,11535],"tags":[14227,40531,5198,99448,99453,67310,57565,99512,4343,99444,99511,73078,65491,2478,24883,99481,99455,2345,99452,99454,22682,99507,99456,99449,99457,99447],"powerkit_post_featured":[],"class_list":["post-563241","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-fr","category-etudes","category-medecine-interne-generale","category-neurologie-fr","category-ophtalmologie","category-rapports-de-congres","tag-azathioprine","tag-depletion-des-cellules-b","tag-eculizumab","tag-efgartigimod","tag-imaavy","tag-immunoglobulines-intraveineuses","tag-inhibiteur-de-lacetylcholinesterase","tag-inhibiteurs-du-complement","tag-ivig","tag-mestinon","tag-modulateurs-de-la-proteine-fcrn","tag-myasthenie-grave","tag-mycophenolate-mofetil","tag-plasmapherese","tag-prednisone","tag-pyridostigmine","tag-ravulizumab","tag-rituximab","tag-rozanolixizumab","tag-soliris","tag-steroides-oraux","tag-syndromes-myastheniques","tag-ultomiris","tag-vyvgart","tag-zilbrysq","tag-zilucoplan","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-10-17 06:01:53","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":564315,"slug":"maggiori-possibilita-grazie-a-classi-di-principi-attivi-innovativi","post_title":"Maggiori possibilit\u00e0 grazie a classi di principi attivi innovativi","href":"https:\/\/medizinonline.com\/it\/maggiori-possibilita-grazie-a-classi-di-principi-attivi-innovativi\/"},"pt_PT":{"locale":"pt_PT","id":564317,"slug":"possibilidades-alargadas-gracas-a-classes-inovadoras-de-principios-ativos","post_title":"Possibilidades alargadas gra\u00e7as a classes inovadoras de princ\u00edpios ativos","href":"https:\/\/medizinonline.com\/pt-pt\/possibilidades-alargadas-gracas-a-classes-inovadoras-de-principios-ativos\/"},"es_ES":{"locale":"es_ES","id":564325,"slug":"mayores-posibilidades-gracias-a-clases-innovadoras-de-principios-activos","post_title":"Mayores posibilidades gracias a clases innovadoras de principios activos","href":"https:\/\/medizinonline.com\/es\/mayores-posibilidades-gracias-a-clases-innovadoras-de-principios-activos\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/563241","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=563241"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/563241\/revisions"}],"predecessor-version":[{"id":564314,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/563241\/revisions\/564314"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/562675"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=563241"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=563241"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=563241"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=563241"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}